The earnings call presented a positive outlook with strong results from clinical trials and a successful product launch, alongside strategic restructuring to achieve financial stability. However, challenges include significant job cuts and discontinuation of certain programs.

Company Guidance

During the Adaptimmune Therapeutics Q3 2024 earnings call, the company provided detailed guidance focusing on strategic objectives and financial metrics. They announced a new strategic business plan aimed at reaching operating cash flow breakeven by 2027, which includes a 33% reduction in headcount and a cost-saving initiative projected to save $506 million in 2025 and $300 million from 2025 to 2028. The company is prioritizing its sarcoma franchise, with a confidence projection of $400 million in combined U.S. peak revenue for their TCR T-cell therapies, Tecelra and lete-cel. With Tecelra recently approved for synovial sarcoma, they have nine authorized treatment centers, with plans to expand to around 30 by the end of 2025. Adaptimmune also reported $186 million in total liquidity at the end of Q3, with further funding options available through their debt facility. They plan to continue focusing on high-potential programs like PRAME and CD70 while suspending investments in earlier-stage pipeline projects.

Positive Results from IGNYTE-ESO Trial

The pivotal IGNYTE-ESO trial with lete-cel met its primary endpoint with a 42% response rate overall, including 6 complete responses. This forms the basis of the BLA submission for lete-cel, expected to expand its reach to synovial sarcoma and MRCLS patients.

Successful Tecelra Launch

Tecelra, the first FDA-approved engineered cell therapy for solid tumors, has been embraced by the sarcoma community with 9 treatment centers authorized. Projected to expand to 30 centers by the end of 2025, achieving patient coverage in sarcoma centers of excellence.

Cost Reduction and Strategic Focus

The company plans a 33% headcount reduction and a 25% reduction in operating expenses by next year, leading to a $506 million saving in 2025, aiming for cash flow breakeven by 2027.

Increased Confidence in Sarcoma Franchise Revenue

The company projects $400 million in combined U.S. peak revenue for TCR T-cell and lete-cel, with lete-cel expected to make up over 60% of the revenue.

---

Adaptimmune Therapeutics (ADAP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADAP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 27, 2025	2024 (Q4)	-0.03 / -	-0.04	―	―	―
Nov 13, 2024	2024 (Q3)	>-0.01 / -0.01	-0.03	66.67% (+0.02)	―
Aug 12, 2024	2024 (Q2)	-0.04 / 0.04	-0.02	300.00% (+0.06)	―
May 15, 2024	2024 (Q1)	-0.15 / -0.03	0	―	―
Mar 06, 2024	2023 (Q4)	-0.17 / -0.04	-0.03	-33.33% (-0.01)	―
Nov 08, 2023	2023 (Q3)	-0.19 / -0.03	-0.25	88.00% (+0.22)	―
Aug 09, 2023	2023 (Q2)	-0.14 / -0.02	-0.05	60.00% (+0.03)	―
May 12, 2023	2023 (Q1)	-0.19 / 0.00	-0.05	―	―
Mar 06, 2023	2022 (Q4)	-0.24 / -0.03	-0.04	25.00% (+0.01)	―	―
Nov 08, 2022	2022 (Q3)	-0.25 / -0.25	-0.05	-400.00% (-0.20)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ADAP Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2024	$0.77	$0.59	-23.38%
Aug 12, 2024	$0.99	$1.09	+10.10%
May 15, 2024	$1.15	$1.24	+7.83%
Mar 06, 2024	$1.46	$1.71	+17.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---